Namrata C. Email and Phone Number

Vetigenics, an animal health biotechnology company, is devoted to improving the health and well-being of pets by making the life-saving benefits of antibody-based therapies available to treat their cancers and other chronic diseases. Our core technology is the first, fully canine phage display library, created from the RNA of actual dogs that rapidly generates novel, safe and effective therapies, now being studied in dogs with cancer.

QSAM Biosciences is a clinical stage company developing next generation nuclear medicines for the treatment of cancer and related diseases and conditions. Our lead product, Samarium-153 DOTMP (AKA CycloSam®), is an advanced radiopharmaceutical with significant potential to treat primary bone cancer, bone metastases and be used for bone marrow ablation. Led all aspects of the Phase 1 clinical trial, and oversaw R&D, manufacturing, supply chain and pipeline development.

Ryca International, Inc. is a dental innovation company with a team of best-in-class engineering, dental, manufacturing, regulatory, design and business experts dedicated to improving lives through effortless and effective oral care products. Addressing the global oral disease epidemic and the fact that 9 out 10 people don’t brush correctly, our flagship product, Encompass, a revolutionary half-mouth toothbrush, prevents user error while providing a flawless cleaning in just 20 seconds.At Ryca, Namrata lends her expertise and leadership to help pursue opportunities that drive growth by targeting funding sources, procuring investments, and managing investor relations; monitoring the marketplace for competitive intelligence and trends; building and supporting strategic partnerships; developing marketing and community engagement strategies.

Spearheaded community engagement and employee relations programs in largest market for leading healthcare insurance company.

Assist small to midsize healthcare companies through various stages of development with special emphasis on capital formation, investor relations and business development.Clients: BioMag, TraumaTec, AngioSoma

SynVivo® is a physiological, cell-based microfluidic platform that provides a morphologically and physiologically realistic microenvironment allowing real-time study of cellular behavior, drug delivery and drug discovery. Strategic planning, direction and execution of investment strategy.Procurement and development of additional sales channels i.e. academic institutions, medical centers, private labs, etc.

NovaScan has developed platform technology that detects the presence of cancer, both ex vivo and in vivo; leverages detection of the Cole relaxation frequency; this varies between one to three orders of magnitude between cancerous and non-cancerous cells. Lead application – skin cancer.Strategic planning, direction and execution of investment strategy to support commercialization of the technology.

For over 30 years, Best Friends Animal Society has been running the nation’s largest no-kill sanctuary for companion animals and building effective programs that reduce the number of animals entering shelters.Managed development and growth of new revenue sources, membership and community awareness through soliciting, negotiating, managing and promoting strategic corporate partnerships.